The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Opdivo’s Japan Patent to Expire in 2031, Ono to Cover LOE with New Launches: Chief
Ono Pharmaceutical's flagship cancer drug Opdivo (nivolumab) will lose its patent protection in Japan in 2031, but the company will work to counter its revenue cliff with the global launches of new products, President Gyo Sagara said on May 10.…
To read the full story
Related Article
- Ono’s Sales Rise 7% on Overseas Growth of Qinlock, Romvimza
October 31, 2025
- Ono’s Profits Slide Over 60% as Deciphera Buyout Costs Swell
May 9, 2025
- Ono’s H1 Revenue Falters 7% after Opdivo Price Cuts
November 1, 2024
- Ono Crosses 500 Billion Yen in FY2023 Sales, Forxiga Drives 9th Year of Growth
May 10, 2024
- Ono Posts Record High H1 Earnings for 6th Consecutive Year Driven by Opdivo
November 2, 2023
- Ono Scores 12.5% Rise in Q1 Revenue on Opdivo, Forxiga
August 1, 2023
- Ono Notches Two-Digit Growth in FY2022; Opdivo en Route to 150 Billion Yen Mark
May 11, 2023
- Ono’s 9-Month Revenue Climbs 25% on Robust Opdivo and Forxiga Sales
February 1, 2023
- Ono Gets Its Hands on Equillium’s Rights to 1st-in-Class CD6 Drug
December 7, 2022
- Ono’s April-September Sales Zoom 24.5% on Bullish Opdivo and Forxiga
November 1, 2022
- Ono Logs Two-Digit Growth in Q1 Earnings on Opdivo
August 2, 2022
- Opdivo Projected to Grow 38% to 155 Billion Yen, but Ono Chief Sees No Re-Pricing
May 12, 2022
- Ono Nets 16.8% Sales Growth on Opdivo, Forxiga; 400 Billion-Plus Yen Eyed for FY2022
May 12, 2022
- Buoyant Opdivo and Forxiga Drive Ono’s Growth in April-December
February 1, 2022
- Ono to Decide on Revision of Scholarship Donation Program by Year-End
November 2, 2021
- Ono Enjoys Double-Digit Growth in H1 on Upbeat Opdivo, Forxiga
November 2, 2021
- Ono’s Q1 Sales Up 16.6% on Opdivo Indication Expansions
August 2, 2021
- Ono Nets 5.8% Revenue Growth in FY2020 on Opdivo, Forxiga
May 12, 2021
- Ono Chief Questions Yet Another Re-Pricing for Opdivo, 11.5% Cut in August
May 12, 2021
- Ono Logs 4.3% Sales Growth in April-December, Opdivo Jumps
February 2, 2021
- Ono Licenses MALT1 Inhibitor for Blood Cancer Treatments from Takeda Spin-Off Chordia
December 16, 2020
- Ono’s Half-Year Operating Profit Up 25.1% on Double-Digit Drop in R&D, SGA Costs Amid COVID-19
October 30, 2020
- Ono’s Q1 Operating Profit Up 35% as SGA, R&D Costs Decrease on COVID-19
August 3, 2020
BUSINESS
- iPark Institute to Launch AI-Based Platform to Link Investors with Startups
January 16, 2026
- Acromegaly Drug Palsonify Meets Primary Endpoint in Japan PII/PIII Trial
January 16, 2026
- Tanabe’s EPP/XLP Drug Hits Main Goals in PIII, Weighs Launch Strategy
January 16, 2026
- Forxiga Generics Reach 11% Share in First Month: Intage
January 16, 2026
- Takeda to Halt Sales of Cell Therapy Alofisel in Japan
January 15, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…